Ablynx NV has named Robert Friesen, an experienced R&D executive, to be its chief scientific officer from 1 March. Dr Friesen succeeds Antonin de Fougerolles who has left the company to become chief executive of Evox Therapeutics Ltd.
Dr Friesen joins from the Dutch biotech company ProQR Therapeutics NV where he led the science and early drug development division. Prior to this, he was global head of biologics research at Janssen BioTherapeutics.
Dr Friesen holds a PhD in biochemistry from the University of Texas and performed postdoctoral research at the University of Groningen in the Netherlands.
Ablynx announced the appointment on 24 January 2018.
Copyright 2018 Evernow Publishing Ltd